Juvenile Idiopathic Arthritis Diagnostic Market Report 2026

The juvenile idiopathic arthritis diagnostic market size has grown strongly in recent years. It will grow from $5.03 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders in children, growing awareness of juvenile idiopathic arthritis, improved availability of serological and imaging tests, expansion of pediatric specialty care, rising use of laboratory diagnostics.

The juvenile idiopathic arthritis diagnostic market size is expected to see strong growth in the next few years. It will grow to $6.6 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancement in molecular and genetic testing technologies, increasing focus on early disease diagnosis, rising investment in pediatric healthcare infrastructure, growing demand for personalized medicine approaches, expansion of diagnostic services in emerging markets. Major trends in the forecast period include early and accurate diagnosis of pediatric autoimmune disorders, growing use of advanced imaging in jia detection, rising adoption of genetic and biomarker-based testing, increasing demand for multimodal diagnostic approaches, expansion of specialized pediatric rheumatology diagnostics.

The rising prevalence of autoimmune disorders is anticipated to drive the growth of the juvenile idiopathic arthritis diagnostic market in the coming years. Autoimmune disorders are conditions in which the immune system erroneously attacks the body's healthy cells, resulting in inflammation, tissue damage, and long-term health complications. The increase in autoimmune diseases is linked to a complex combination of environmental triggers, genetic susceptibility, and lifestyle factors. Autoimmune diseases contribute to juvenile idiopathic arthritis (JIA) by causing the immune system to mistakenly target the synovial tissue in joints, leading to inflammation and damage. For example, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization dedicated to global MS research and advocacy, reported that an estimated 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune disease, in 2023. Consequently, the growing prevalence of autoimmune disorders is fueling the expansion of the juvenile idiopathic arthritis diagnostic market.

Major companies operating in the juvenile idiopathic arthritis diagnostic market are emphasizing strategic partnerships to broaden their product portfolios, enhance research capabilities, and strengthen their global market presence. Strategic partnerships refer to collaborations between organizations aimed at advancing early detection and diagnosis. For example, in November 2024, Augurex Life Sciences Corp., a Canada-based biotechnology company, partnered with Quest Diagnostics, a US-based diagnostic services company, to improve the diagnosis and management of rheumatoid arthritis (RA) using the 14-3-3η (eta) biomarker. Under the collaboration, Quest Diagnostics will validate and provide a lab-developed test in the United States based on Augurex’s 14-3-3η biomarker. The test is designed to detect elevated levels of the 14-3-3η protein, which is associated with rheumatoid arthritis and linked to higher disease severity and risk of joint damage.

In September 2023, Globus Medical Inc., a US-based medical device company, merged with NuVasive Inc. to provide surgeons and patients with a comprehensive range of musculoskeletal procedural solutions and advanced technologies, enhancing the overall continuum of care. The combined entity is expected to strengthen complementary global operations, expand its market presence, and significantly broaden its portfolio in arthritis and orthopedic treatment solutions. NuVasive, Inc. is a US-based medical device company that focuses on developing medical devices and procedures for orthopedic and idiopathic conditions.

Major companies operating in the juvenile idiopathic arthritis diagnostic market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, DiaSorin S.p.A., Sysmex Corporation, Beckman Coulter Inc., BD Biosciences, Agilent Technologies, Merck KGaA, Illumina Inc., Qiagen N.V., Hologic Inc., PerkinElmer Inc., Ortho Clinical Diagnostics, Grifols S.A., Fujirebio, Randox Laboratories.

North America was the largest region in the juvenile idiopathic arthritis diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the juvenile idiopathic arthritis diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the juvenile idiopathic arthritis diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the juvenile idiopathic arthritis diagnostic market by increasing the cost of imported diagnostic reagents, imaging equipment components, and advanced molecular testing kits. Serological and genetic testing segments are most affected, particularly in north america and asia-pacific regions that rely heavily on cross-border sourcing of diagnostic technologies. Hospital laboratories and diagnostic centres face higher procurement costs, which can affect test pricing and adoption. However, tariffs have also encouraged local manufacturing of diagnostic consumables and reagents, supporting supply chain resilience and long-term cost stabilization.

The juvenile idiopathic arthritis diagnostic market research report is one of a series of new reports that provides juvenile idiopathic arthritis diagnostic market statistics, including juvenile idiopathic arthritis diagnostic industry global market size, regional shares, competitors with a juvenile idiopathic arthritis diagnostic market share, detailed juvenile idiopathic arthritis diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the juvenile idiopathic arthritis diagnostic industry. This juvenile idiopathic arthritis diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Juvenile idiopathic arthritis (JIA) diagnostic refers to the medical procedures and tests used to detect JIA, a chronic autoimmune disorder in children that leads to persistent joint inflammation, pain, and stiffness, which can result in long-term joint damage and mobility challenges. It occurs when an overactive immune system mistakenly attacks the body's own joint tissues due to genetic and environmental factors, causing inflammation that, if untreated, may lead to growth issues, vision complications, and a lower quality of life.

The primary types of juvenile idiopathic arthritis diagnostics include serological tests, imaging tests, and genetic tests. Serological tests involve blood analysis to detect specific markers that indicate inflammation or autoimmune activity related to JIA. Key technologies employed in JIA diagnostics include molecular diagnostics, immunoassays, and flow cytometry. The services provided cover diagnostic services, consultation services, and laboratory services, and are implemented in various settings, such as hospital laboratories, diagnostic centers, and research institutes.

The juvenile idiopathic arthritis diagnostic market consists of revenues earned by entities by providing services such as clinical evaluations, blood tests, ophthalmologic screenings, bone density scans, and synovial fluid analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile idiopathic arthritis diagnostic market also includes sales of bone density scanners, AI-based diagnostic software, imaging equipment, and biomarker-based diagnostic panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.